Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation pembrolizumab after chemoradiotherapy in locally advanced nasopharyngeal carcinoma
KCT0004637Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in nasopharyngeal carcinoma (NPC), sponsored by Seoul National University Hospital. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on KCT0004637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004637.